Nuevolution is a Scandinavian biopharmaceutical company. The company uses their proprietary DNA-encoded drug discovery platform Chemetics to identify and develop small molecule drugs for tough-to-treat diseases. The business model revolves around collaboration partnerships and out-licensing of projects. Lead program RORyt inverse agonist was licensed to Almirall in 2016. The business model allows for multiple programs to be run simultaneously, mitigating some development risk.